Er Dong Hua
Direktor/Vorstandsmitglied bei Hua Medicine (Shanghai) Co., Ltd.
Aktive Positionen von Er Dong Hua
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
6 Dimensions Capital
6 Dimensions Capital Investment ManagersFinance 6 Dimensions Capital is an independent private equity firm headquartered in China. The firm was founded in 2017. | Private Equity Investor | 18.05.2017 | - |
Hua Medicine (Shanghai) Co., Ltd.
Hua Medicine (Shanghai) Co., Ltd. BiotechnologyHealth Technology Hua Medicine (Shanghai) Co., Ltd. is a Chinese biotechnology company that focuses on the clinical needs of diabetic patients. The private company is based in Shanghai, China. The company has brought together high-end talents and scientific and technological resources to develop the world's first dorzagliatin (hms5552) for the treatment of type 2 diabetes. Hua Medicine has conducted two phase III clinical trials in 2019, targeting type 2 diabetes patients who have failed to treat the disease with other medications. The company plans to expand the advanced concepts of personalized therapy and management of diabetes to achieve effective control of diabetes and metabolic diseases and complications. The company was founded in 2011 by Li Chen, who has been the CEO since then. | Direktor/Vorstandsmitglied | - | - |
Karriereverlauf von Er Dong Hua
Ehemalige bekannte Positionen von Er Dong Hua
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
Frontline Bioventures | Direktor/Vorstandsmitglied | - | 18.05.2017 |
Statistik
International
China | 4 |
Operativ
Director/Board Member | 2 |
Private Equity Investor | 1 |
Sektoral
Finance | 3 |
Health Technology | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Private Unternehmen | 3 |
---|---|
Frontline Bioventures | Finance |
6 Dimensions Capital
6 Dimensions Capital Investment ManagersFinance 6 Dimensions Capital is an independent private equity firm headquartered in China. The firm was founded in 2017. | Finance |
Hua Medicine (Shanghai) Co., Ltd.
Hua Medicine (Shanghai) Co., Ltd. BiotechnologyHealth Technology Hua Medicine (Shanghai) Co., Ltd. is a Chinese biotechnology company that focuses on the clinical needs of diabetic patients. The private company is based in Shanghai, China. The company has brought together high-end talents and scientific and technological resources to develop the world's first dorzagliatin (hms5552) for the treatment of type 2 diabetes. Hua Medicine has conducted two phase III clinical trials in 2019, targeting type 2 diabetes patients who have failed to treat the disease with other medications. The company plans to expand the advanced concepts of personalized therapy and management of diabetes to achieve effective control of diabetes and metabolic diseases and complications. The company was founded in 2011 by Li Chen, who has been the CEO since then. | Health Technology |
- Börse
- Insiders
- Er Dong Hua
- Erfahrung